Systematic review on factors associated with medication non-adherence in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 18, Issue 10, 2012, Pages 1053-1061

  Daley, David James ^a,b   Myint, Phyo Kyaw ^a,b   Gray, Richard John ^c   Deane, Katherine Helen O'Leary ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

Author keywords

Factors; Medication; Non adherence; Parkinson's disease

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; LEVODOPA;

ADULT; AGE DISTRIBUTION; BEHAVIOR; CASE CONTROL STUDY; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; EDUCATION; EMPLOYMENT STATUS; FEMALE; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC PARKINSON DISEASE; INTERNAL VALIDITY; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTICENTER STUDY; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SPOUSE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIPARKINSON AGENTS; HUMANS; MEDICATION ADHERENCE; OUTPATIENTS; PARKINSON DISEASE; PREVALENCE; RISK FACTORS;

EID: 84870562182     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.09.004     Document Type: Review

References (39)

1. Chaudhuri K., Taurah L., MacMahon D. PD life: a prospective multi-centre longitudinal audit of quality of life in Parkinson's disease across the UK. J Neurol Neurosurg Psychiatr 2004, 75:516.
2. Rajput A. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 2001, 8:95.
3. Leoni O., Martignoni E., Cosentino M., Michielotto D., Calandrella D., Zangaglia R., et al. Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf 2002, 11:149-157.
4. Grosset K.A., Reid J.L., Grosset D.G. Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Mov Disord 2005, 20:1397-1404.
5. Grosset D., Antonini A., Canesi M., Pezzoli G., Lee A., Shaw K., et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009, 24:826-832.
6. NICE Medicines adherence: involving patients in decisions about prescribed medications and supporting adherence. NICE Clinical Guidelines 76 2009, Developed by the National Collaborative Centre for Primary Care.
7. Leopold N.A., Polansky M., Hurka M.R. Drug adherence in Parkinson's disease. Mov Disord 2004, 19:513-517.
8. Kulkarni A.S., Balkrishnan R., Anderson R.T., Edin H.M., Kirsch J., Stacy M.A. Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson's disease. Mov Disord 2008, 23:359-365.
9. Grosset K.A., Bone I., Grosset D.G. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005, 20:1502-1507.
10. Bainbridge J.L., Ruscin J. Challenges of treatment adherence in older patients with Parkinson's disease. Drugs Aging 2009, 26:145-155.
11. Von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007, 370:1453-1457.
12. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology. J Am Med Assoc 2000, 283:2008-2012.
13. Banks P., Lawrence M. The disability discrimination act, a necessary, but not sufficient safeguard for people with progressive conditions in the workplace? The experiences of younger people with Parkinson's disease. Disabil Rehabil 2006, 28:13-24.
14. Valldeoriola F., Coronell C., Pont C., Buongiorno M.T., Cámara A., Gaig C., et al. Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study. Eur J Neurol 2010, 1-8.
15. Evans A.H., Lawrence A.D., Potts J., Appel S., Lees A.J. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005, 65:1570-1574.
16. WHO Adherence to long term therapies: evidence for action 2003.
17. Cramer J. A systematic review of adherence with medications for diabetes. Diabetes Care 2004, 27:2285.
18. Lingam R., Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002, 105:164-172.
19. Setter S.M. Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson's disease. Neurol Clin 2008, 26:45-63.
20. Katon W., Ciechanowski P. Impact of major depression on chronic medical illness. J Psychosom Res 2002, 53:859-864.
21. DiMatteo M.R., Lepper H.S., Croghan T.W. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000, 160:2101-2107.
22. Shiba M., Bower J.H., Maraganore D.M., McDonnell S.K., Peterson B.J., Ahlskog J.E., et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000, 15:669-677.
23. Poewe W., Seppi K. Treatment options for depression and psychosis in Parkinson's disease. J Neurol 2001, 248:12-21.
24. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-458.
25. Grosset D. Therapy adherence issues in Parkinson's disease. J Neurol Sci 2010, 289:115-118.
26. Mizuno Y., Takubo H., Mizuta E., Kuno S. Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism Relat Disord 2003, 9(Suppl. 1):3-9.
27. Newman E., Grosset D., Kennedy P. The Parkinsonism-hyperpyrexia syndrome. Neurocrit Care 2009, 10:136-140.
28. Ceravolo R., Frosini D., Rossi C., Bonuccelli U. Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord 2009, 15(Suppl. 4):S111-S115.
29. Chambers R.A., Taylor J.R., Potenza M.N. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Pychiat 2003, 160:1041.
30. Saini S.D., Schoenfeld P., Kaulback K., Dubinsky M.C. Effect of medication dosing frequency on adherence in chronic diseases. Methods 2007.
31. LeWitt P.A., Lyons K.E., Pahwa R., Group obotSS Advanced Parkinson disease treated with rotigotine transdermal system. Neurology 2007, 68:1262-1267.
32. Schnitzler A., Leffers K.-W., Hack H.-J. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease. Parkinsonism Relat Disord 2010, 16:513-516.
33. Tarrants M.L., Denarie M.F., Castelli-Haley J., Millard J., Zhang D. Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence. Am J Geriatr Pharmacother 2010, 8:374-383.
34. Fargel M., Grobe B., Oesterle E., Hastedt C., Rupp M. Treatment of Parkinsons disease: a survey of patients and neurologists. Clin Drug Invest 2007, 27:207-218.
35. Stilley C.S., Bender C.M., Dunbar-Jacob J., Sereika S., Ryan C.M. The impact of cognitive function on medication management: three studies. Health Psychol 2010, 29:50.
36. Arlt S., Lindner R., Rosler A., von Renteln-Kruse W. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging 2008, 25:1033-1047.
37. Grosset K.A., Grosset D.G. Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial. BMC Neurol 2007, 7:20.
38. Gray R., White J., Schulz M., Abderhalden C. Enhancing medication adherence in people with schizophrenia: an international programme of research. Int J Mentl Health Nurs 2010, 19:36-44.
39. Daley D., Deane K., Gray R., Worth P., Clark A., Sabanathan K., et al. The use of career assisted adherence therapy for people with Parkinson's disease and their careers (CAAT-PARK): study protocol for a randomised controlled trial. Trial 2011, 12:251.